| Medical and Health Sciences | Lifetime | 32 | US 16 | 100.00 |
| Medical and Health Sciences | 2021-2025 | 565 | US 195 | 99.88 |
| Cardiology and Cardiovascular Medicine | Lifetime | 15 | US 12 | 99.99 |
| Surgery | Lifetime | 46 | US 28 | 99.96 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 47 | US 25 | 99.85 |
| Pulmonary and Respiratory Medicine | Lifetime | 128 | US 67 | 99.83 |
| Organizational Behavior and Human Resource Management | Lifetime | 292 | US 148 | 99.17 |
| Public, Environmental and Occupational Health | Lifetime | 739 | US 383 | 98.95 |
| Internal Medicine | Lifetime | 60 | US 21 | 98.71 |
| Epidemiology | Lifetime | 966 | US 490 | 98.70 |
| Family Practice | Lifetime | 41 | US 22 | 97.67 |
| Immunology | Lifetime | 724 | US 373 | 97.72 |
| Hematology | Lifetime | 556 | US 279 | 95.90 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 136 | US 65 | 99.32 |
| Surgery | 2021-2025 | 459 | US 180 | 96.36 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 266 | US 93 | 94.93 |
| Pathology and Forensic Medicine | 2021-2025 | 577 | US 183 | 59.10 |
| Cardiac Imaging and Diagnostics | Lifetime | 7 | US 5 | 99.98 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 8 | US 6 | 99.96 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 5 | US 3 | 99.91 |
| Cardiovascular Disease and Adiposity | Lifetime | 10 | US 8 | 99.91 |
| Cardiovascular Health and Risk Factors | Lifetime | 3 | US 2 | 99.89 |
| Cerebrovascular and Carotid Artery Diseases | Lifetime | 10 | US 3 | 99.93 |
| Coronary Interventions and Diagnostics | Lifetime | 12 | US 8 | 99.96 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 27 | US 11 | 99.84 |
| Lipoproteins and Cardiovascular Health | Lifetime | 19 | US 11 | 99.85 |
| Acute Myocardial Infarction Research | Lifetime | 29 | US 19 | 99.89 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 38 | US 19 | 99.87 |
| Cardiac, Anesthesia and Surgical Outcomes | Lifetime | 63 | US 34 | 99.74 |
| Cardiovascular Function and Risk Factors | Lifetime | 114 | US 75 | 99.76 |
| Global Public Health Policies and Epidemiology | Lifetime | 25 | US 8 | 99.51 |
| Cardiac Valve Diseases and Treatments | Lifetime | 123 | US 76 | 99.70 |
| Health and Medical Research Impacts | Lifetime | 20 | US 10 | 98.90 |
| Cardiovascular Health and Disease Prevention | Lifetime | 78 | US 36 | 99.45 |
| Aortic Thrombus and Embolism | Lifetime | 5 | US 3 | 98.82 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 173 | US 85 | 99.41 |
| Medication Adherence and Compliance | Lifetime | 36 | US 29 | 99.05 |
| Pulmonary Hypertension Research and Treatments | Lifetime | 114 | US 54 | 99.20 |
| Cardiac and Coronary Surgery Techniques | Lifetime | 70 | US 44 | 99.03 |
| Blood Pressure and Hypertension Studies | Lifetime | 191 | US 87 | 99.34 |
| Cardiovascular Issues in Pregnancy | Lifetime | 85 | US 38 | 98.95 |
| Cardiac Arrhythmias and Treatments | Lifetime | 281 | US 144 | 99.19 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 197 | US 94 | 99.01 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 353 | US 193 | 99.00 |
| Peripheral Artery Disease Management | Lifetime | 196 | US 129 | 98.55 |
| Cardiac Health and Mental Health | Lifetime | 175 | US 106 | 98.49 |
| Cardiovascular Effects of Exercise | Lifetime | 203 | US 100 | 98.63 |
| Pharmaceutical Economics and Policy | Lifetime | 119 | US 66 | 97.98 |
| Cardiac Structural Anomalies and Repair | Lifetime | 429 | US 273 | 98.72 |
| Blood Coagulation and Thrombosis Mechanisms | Lifetime | 288 | US 107 | 97.97 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 426 | US 189 | 98.56 |
| Cardiac tumors and thrombi | Lifetime | 234 | US 118 | 97.72 |
| Congenital Heart Disease Studies | Lifetime | 616 | US 345 | 97.79 |
| Advanced MRI Techniques and Applications | Lifetime | 962 | US 449 | 97.95 |
| Platelet Disorders and Treatments | Lifetime | 459 | US 181 | 97.54 |
| Infective Endocarditis Diagnosis and Management | Lifetime | 725 | US 315 | 97.39 |
| Aortic Disease and Treatment Approaches | Lifetime | 683 | US 346 | 97.37 |
| Aortic aneurysm repair treatments | Lifetime | 698 | US 349 | 96.65 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 631 | US 254 | 95.94 |
| Health Promotion and Cardiovascular Prevention | Lifetime | 199 | US 49 | 95.93 |
| Hemodynamic Monitoring and Therapy | Lifetime | 799 | US 327 | 96.07 |
| Health and Lifestyle Studies | Lifetime | 649 | US 211 | 95.58 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 298 | US 116 | 94.52 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 771 | US 339 | 93.89 |
| Cardiac Fibrosis and Remodeling | Lifetime | 616 | US 221 | 92.76 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 226 | US 74 | 90.75 |
| Pericarditis and Cardiac Tamponade | Lifetime | 612 | US 267 | 88.18 |
| Global Health and Epidemiology | Lifetime | 790 | US 142 | 63.17 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 13 | US 8 | 98.85 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 82 | US 29 | 99.16 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 310 | US 127 | 97.72 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 92 | US 54 | 95.18 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 180 | US 51 | 93.67 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 229 | US 79 | 95.31 |
| Medication Adherence and Compliance | 2021-2025 | 117 | US 47 | 91.72 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 181 | US 37 | 91.62 |
| Coronary Interventions and Diagnostics | 2021-2025 | 803 | US 169 | 91.73 |
| Pharmaceutical Economics and Policy | 2021-2025 | 228 | US 88 | 88.48 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 728 | US 144 | 85.94 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 905 | US 205 | 84.46 |
| Cardiac Ischemia and Reperfusion | 2021-2025 | 994 | US 129 | 58.64 |
